[1] Prostate cancer-NCCN Guidelines Version 1.2023. [2] Prostate Cancer-NCCN Guidelines Version 4.2022. [3] Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metas...
戈舍瑞林微球已于2023年6月作为2.2类新药获批上市,成为前列腺癌患者去势治疗的重要选择之一。 参考文献 参考文献: [1] Prostate cancer-NCCN Guidelines Version 4.2023. [2] Prostate Cancer-NCCN Guidelines Version 4.2022. [3] Prostate...
2023年5月,FDA批准奥拉帕利联合阿比特龙治疗BRCA突变mCRPC成人患者。根据PROpel试验的结果,奥拉帕利/阿比特龙被纳入NCCN指南,作为有致病性BRCA1或BRCA2突变(胚系和/或体细胞),且尚未接受新型激素疗法或多西他赛治疗的mCRPC患者(1类),以及既往在去势敏感情况下接受过多西他赛治疗的mCRPC患者(2A类)的一线可选方案。 ▲2023年...
2023年5月,FDA批准奥拉帕利联合阿比特龙治疗BRCA突变mCRPC成人患者。根据PROpel试验的结果,奥拉帕利/阿比特龙被纳入NCCN指南,作为有致病性BRCA1或BRCA2突变(胚系和/或体细胞),且尚未接受新型激素疗法或多西他赛治疗的mCRPC患者(1类),以及既往在去势敏感情况下接受过多西他赛治疗的mCRPC患者(2A类)的一线可选方案。 ▲2023年...
参考文献: NCCN Clinical Practice Guidelines in Oncology:Prostate Cancer(Version 1.2023). 本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容,不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的,本平台不承担相关责任。本平台对发布的内容,并不代表同意...
[3] Prostate Cancer-NCCN Guidelines Version 2.2023. [4] de Bono JS, Mehra N, Scagliotti GV, et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet ...
NCCNGuidelinesVersion4.2023 Comprehensive IatieafCantents Cancer NCCNProstateCancerDmsunnion Network SYSTEMICTHERAPYFORCASTRATION-SENSITIVEPROSTATECANCER Monitortingtpreferred)| Mo*s,or ADruuu|See |Studies Systemis |Physicalexam+nogatlve Therapyfot
Kidney Cancer “At this point in time, we have no studies with a background of individuals who have experienced disease progression on a contemporary doublet... We want that to change.” —Eric Jonasch, MD The key updates to the NCCN Guidelines in kidney cancer were centered on subsequent...
[3] NCCN Clinical Practice Guidelines in Oncology:Prostate Cancer Early Detection(Version 1.2023) 编辑:Gardenia 审校:Rudolf 执行:Uni 本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容,不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议。如该等信息被用于了...
NCCN Guidelines Version 1.2023Table of ContentsLung Cancer Screening DiscussionInga T. Lennes, MD, MPH, MBA ? Douglas E. Wood, MD/Chair ? Jacob Sands, MD ? Massachusetts General Hospital Cancer CenterFred Hutchinson Cancer Center Dana-Farber/Brigham and Women''s Cancer Center Matthew B. Scha...